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ABSTRACT 
 
Utility measures are used in cost-effectiveness studies to represent the effect a given 
outcome or intervention has on quality of life. Pills are common interventions used to try 
to reduce the risk of an adverse health outcome.  The utility value for taking pills is often 
estimated or assumed to be 1.0, suggesting no effect on quality of life, but I wondered 
whether any studies had been published that quantified this utility value.  This master’s 
paper has two goals.  In the systematic review portion, I searched for published articles 
that quantified the utility of taking pills for preventive purposes.  In the original research 
portion, I report the results of a study that quantified the utility value of taking pills to 
prevent an adverse health outcome. 
For the review, I systematically searched PUBMED using strategically selected 
keywords. This strategy was supplemented with a search of the Cochrane database, a 
hand search of bibliographies, and questioning of experts.  Studies that calculated a utility 
value were included.  I expanded the inclusion criteria to any article that cited a utility 
value for pill-taking for preventive purposes in adults. In the original research, we invited 
healthcare system employees to participate in an online survey about taking pills. We 
calculated mean utility values for taking pills and compared utility values across several 
demographic characteristics and by numeracy level. 
I found two published articles that quantified the utility value of taking aspirin 
and warfarin.  I found a total of nineteen additional published articles that cite a utility 
value for taking pills for preventive purposes.  All these values ranged from 0.95 – 1.0, 
depending on the type of pills. Through our original research project involving 708 
adults, we found that the average utility value for taking one pill per day is 0.997. This 
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value did not vary significantly by age, sex, race, education level, income level, or 
number of pills taken per day. Those with low numeracy level tended to have slightly 
lower utility values.   
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What is the Effect of Pill-taking on Quality of Life: A Systematic Review of the 
Utility Value for Taking Pills 
 
 
ABSTRACT 
BACKGROUND: Utility measures are used in cost-effectiveness studies to represent the 
effect a given outcome or intervention has on quality of life. Pills are common 
interventions used to try to reduce the risk of an adverse health outcome.  The utility 
value for taking pills is often estimated or assumed to be 1.0, indicating no effect on 
quality of life, but I was not aware of any studies that specifically aimed to quantify this 
utility value.  
OBJECTIVE:  To systematically search for and identify published articles that attempt to 
quantify the utility of taking pills for preventive purposes. 
METHODS: I systematically searched PUBMED using strategically selected keywords. 
This strategy was supplemented with a search of the Cochrane database, a hand search of 
bibliographies, and questioning of experts.  Studies that cited a utility value were also 
included. 
RESULTS:  I found two studies in which investigators interviewed 74 patients and 83 
patients and determined the utility values for taking daily aspirin to be 0.998 in both 
studies and daily warfarin (plus its monitoring) to be 0.987 in one study and 0.988 in the 
other.  I found nineteen additional studies that cited a specific utility value that varied 
from 0.95 to 1.0, depending on the type of pill and whether or not side effects and/or drug 
monitoring were included in the utility value. 
CONCLUSIONS: I found two studies that quantified a utility value for pill-taking, 
although both studies were limited by a small sample size. 
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INTRODUCTION: 
Most adults will end up taking daily pills at some point in their lives.  Many 
adults take multiple pills, often more than once per day.  When people take pills they 
must go through a process that involves, but is not limited to, obtaining the pills, paying 
for them, ingesting the pills, dealing with any side effects which the pills may cause, and 
remembering to take the pills.  If the pills require a prescription, the process also includes 
visits to clinicians and pharmacists. These processes, part of the routine of “taking pills,” 
can theoretically affect quality of life. 
When people take pills on a daily basis, they do so either to try to prevent an 
undesired health outcome or to treat a specific condition and/or its symptoms.   In both 
cases, there may be some diminution in quality of life.  Side effects of pills aside, the 
effects of pill-taking on quality of life are likely to vary not only based on the reason 
people take pills but also on other factors such as number of pills taken per day, number 
taken at one time, and even the size of the pills.  In health studies, effects on quality of 
life are often measured by assigning a numerical value that represents the relative quality 
of life effect that a certain health state carries versus a standard state.  This numerical 
value is termed a “utility.”  Utilities range from 0 to 1, with 0 representing death and 1 
representing perfect health. 
There are many studies that address patient adherence and compliance based on 
quantity and complexity of prescribed medication regimens, as well as studies that 
attempt to quantify patient utilities for outcomes of certain diseases.1-3 However I was 
unaware of any study that quantified the utility value of taking pills.  The overarching 
goal of this systematic review was to identify published studies that either specifically 
	   6	  
sought to quantify how the act of taking pills affects quality of life or that used a specific 
utility value of taking pills as part of the study. 
 
METHODS 
Eligibility Criteria 
I sought any study that met the following criteria: (1) human subjects older than 
18 years, and (2) determined a utility value of taking pills. Because of an initial low yield 
of such studies, I expanded the review to include any study that used a utility value for 
taking pills.  Non-English language studies were excluded. 
Search Strategy 
 To identify relevant studies, a search of the MEDLINE database was conducted 
using the following search: ((((cost-utility[Title]) OR cost-effectiveness[Title]))) AND 
(((prophylaxis[Title]) OR prevention[Title])). This strategy was supplemented with a 
search of the Cochrane database, a hand search of bibliographies, and questioning of 
experts.  I reviewed the titles and abstracts of the articles identified by the searches, as 
well as any relevant Methods sections, and excluded the studies that did not meet 
eligibility criteria. 
Data Abstraction 
 Data abstracted from relevant studies included study design, year, country, 
medication regimen, utility value, utility range (if given), and the method of utility 
assessment.  
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RESULTS 
A PubMed search yielded 779 results.  After exclusion of non-English and non-
Human results, 643 results remained.  After reviewing the titles, abstracts, and methods 
sections, 12 results remained.  A hand search of those 12 studies’ references yielded 
another 8 results that had not already been reviewed. (Figure 1) 
Two studies were found that included a systematic method to quantify the utility 
of taking pills.4-5  In the first study, the investigators interviewed 74 subjects about 
preferences for various health states as well as taking daily aspirin and warfarin.4 Some 
subjects were unable to understand the time trade-off concept so they were excluded from 
the analysis, leaving a sample size of 57 subjects.  Utilities for taking pills were assessed 
using a computerized utility assessment tool utilizing the time trade-off method.  The 
mean utility value for taking aspirin was 0.998, and the mean utility for taking warfarin 
was 0.988. It is important to note that the utility value for taking warfarin included the 
utility of the routine therapeutic monitoring (i.e., INR checks) every 4 weeks, avoiding 
contact sports and avoiding excessive alcohol consumption.  Similarly, in the second 
study, the investigators interviewed 83 subjects using a time trade-off method to assess 
the utility value of taking aspiring and warfarin, as well as other health states.5 Thirteen 
subjects were excluded due to either difficulty understanding the time trade-off concept, 
inability to understand 1 or more questions, or time constraints for the interview. 
Responses of the 70 remaining patients were analyzed and the mean utility value for 
taking aspirin was 0.998, and the mean utility value for taking warfarin was 0.987.  
 A total of eighteen (18) additional studies were found that cite an estimated 
utility value of taking pills.3,6-22 These were located by initial review and by hand 
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searching bibliographies and questioning experts.  All studies included in this review 
cited a utility value between 0.95 – 1.0, varying depending on the type of medication, 
whether or not side effects of the medication are considered, and in the case of anti-
coagulants, whether INR monitoring is considered (Table).  Additionally, all of the 
studies except two were either decision analyses, or analyses of cost-effectiveness, cost-
benefit, or comparative-effectiveness of taking a medication for a specific purpose on a 
daily basis.  The medications included in the studies were: aspirin,4-8,10,12-19,21 warfarin, 4-
5,8-10,12-15,21 statins,11,17,20 anti-hypertensives,3,22 aspirin + clopidogrel,7,21 apixaban,12,19 
rivaroxaban,13,19 ximelagatran,15 and dabigatran.10,19,21 The studies varied on their source 
for the utility value. Most of these studies derived their utility value from another study 
included in this review; 6-16,19,21 one did not specifically cite a reference for its utility 
values;17 another three used the author’s judgment; 3,18,20 and one used physician 
surveys.11 
 
DISCUSSION 
 In this systematic review, I found two studies whose primary goals included 
attempting to quantify a specific utility value or range of utility values for taking pills,4-5 
though both of these studies was limited by small sample sizes of 57 and 70.  The studies 
determined two utility values that differed based on the type of medication, aspirin or 
warfarin.  Additionally, I found eighteen other studies that cited a specific utility value.3,6-
22 The utility values varied from 0.95 to 1.0, the latter of which would indicate no quality 
of life effect of taking pills, which is unlikely.  Although the utility value for taking pills 
is certainly less than 1.0, it is likely very close to 1.0, as most of the included studies 
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suggest. Deriving a precise value for the utility of taking pills would be important not 
only for issues of clinical decision making, but also pharmaceutical research, health 
policy, and cost-effectiveness research.  One study included in this review discussed 
whether cost-effectiveness of taking aspirin for cardiovascular disease prevention was 
sensitive to the assigned utility of the pill.16 For their base case, the authors used a utility 
value of 1.0. Then they examined and reported the cost per quality-adjusted life-year 
(QALY) gained across a variety of potential utility values.  In their analysis, using a 
utility value of about 0.9996 caused an increase in the cost per QALY above the accepted 
cost-effective threshold of $50,000/QALY.  Their study demonstrates the importance of 
having an accurate utility value when calculating cost-effectiveness. 
Limitations 
 The key limitation to this review is that a variety of different terms are used to 
refer to the actual utility value for which I was looking.  For example, “utility” is 
sometimes described as disutility, quality of life, health effect, and health-related quality 
of life.  This variation made it difficult to find applicable studies that include a utility 
value.   Therefore, there are likely additional studies that refer to a utility value of taking 
pills that were not found upon the literature search for this systematic review. 
Future Research 
Given the lack of direct assessment of the utility value of taking pills, a beneficial 
topic of future research would be a specific patient-centered assessment of this utility 
value.  Determination of the utility value applied by patients will likely vary depending 
on specific pill characteristics, side effects, patient difficulty in obtaining medication 
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(including costs), quantity of pills taken, reason for taking the pills, as well as the specific 
utility measurement tool used. 
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Table. Studies Included in Review 
Study  Utility Value Medication 
Type 
Utility Range Study Type Comments 
Augustovski, 
et. al 
0.999 Aspirin 0.985 – 1.0 Decision 
analysis 
Cites: Naglie 
Coleman, et. 
al 
0.996 
0.987 
Aspirin 
Clopidogrel+ 
  Aspirin 
0.95 – 1.0 
0.95 – 1.0  
Cost-
effectiveness 
analysis 
Cites: Gage 
(1996), O’Brien, 
Freeman; 
Estimate for 
Clopidogrel+ 
   Aspirin 
Davidson, et. 
al 
0.998 
0.987 
Aspirin 
Warfarin 
None given Cost-
effectiveness 
analysis 
Cites: Gage 
(1996) 
Eckman, et. 
al 
0.99 Warfarin None given Cost-
effectiveness 
analysis 
Cites: Gage 
(1996) 
Freeman, et. 
al 
0.998 
0.994 
0.987 
Aspirin 
Dabigatran 
Warfarin 
0.994 – 1.0 
0.975 – 1.0 
0.953 – 1.0 
Cost-
effectiveness 
analysis 
Cites: Gage 
(1996), O’Brien 
Gage, et. al 
(1995) 
0.998 
0.988 
Aspirin 
Warfarin 
0.96 – 1.0 
0.92 – 1.0 
Cost-
effectiveness 
analysis 
57 patient 
interviews using 
time trade-off 
method 
Gage, et. al 
(1996) 
0.998 
0.987 
Aspirin 
Warfarin 
0.994 – 1.0 
0.953 – 1.0 
Cross-sectional 
study with 
patient 
interviews 
70 patient 
interviews using 
time trade-off 
method 
Greving, et. 
al 
0.999 Statin None given Cost-
effectiveness 
analysis 
Cites: Pignone 
(2006), 
Augustovski, 
Naglie 
Lee, et. al 0.998 
0.994 
0.987 
Aspirin 
Apixaban 
Warfarin 
 
0.994 – 1.0 
0.975 – 1.0 
0.940 – 1.0 
Cost-
effectiveness 
analysis 
Cites: Freeman 
Lee, et. al 0.998 
0.994 
0.987 
Aspirin 
Rivaroxaban 
Warfarin 
 
0.994 – 1.0 
0.975 – 1.0 
0.940 – 1.0 
Cost-
effectiveness 
analysis 
Cites: O’Brien, 
Gage (1996) 
Naglie, et. al 0.999 
0.990 
Aspirin 
Warfarin 
0.985 – 1.0 
0.95-1.0 
Decision 
analysis 
Cites: Torrance, 
Weinstein 
O’Brien, et. 
al 
0.998 
0.987 
0.989 
Aspirin 
Warfarin 
Ximelagatran   
0.994 – 1.0 
0.953 – 1.0 
0.986 – 0.991 
Cost-
effectiveness 
analysis 
Cites: Gage 
(1996) 
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0.994 
(< 6 months) 
Ximelagatran   
(> 6 months) 
 
0.993 – 0.996 
Ximelagatran 
utilities from 
physician survey 
Pignone, et. 
al (2006) 
1.0 
1.0 
Aspirin 
Statins 
 
Used for 
sensitivity 
analysis, but 
range not given 
Cost-utility 
analysis 
No reference 
given; Utility 
value varied in 
sensitivity 
analysis 
Pignone, et. 
al (2007) 
1.0 Aspirin Used for 
sensitivity 
analysis, but 
range not given 
Cost-utility 
analysis 
Cites: Naglie; 
Utility value 
varied in 
sensitivity 
analysis 
Pignone, et. 
al (2013) 
0.999 Aspirin  Cost-utility 
analysis 
Assumption 
Pink, et al. 0.998 
0.998 
0.998 
0.998 
0.987 
Aspirin 
Apixaban 
Dabigatran 
Rivaroxaban 
Warfarin 
Probabilistic 
sensitivity 
analysis, but 
range not given 
Comparative 
effectiveness 
analysis 
Cites: Gage 
(1996) 
Pletcher, et. 
al 
1.0 Statins None given Cost-
effectiveness 
analysis 
Clinical judgment 
Shah, et. al 0.998 
0.998 
 
0.987 
0.994 
Aspirin 
Aspirin + 
Clopidogrel 
Warfarin 
Dabigatran 
0.994 – 1.0 
0.994 – 1.0 
 
0.953 – 1.0 
0.990 – 0.998 
Cost-
effectiveness 
analysis 
Cites: Gage 
(1996) 
Torrance, et. 
al (1987) 
0.95 – 0.99 Anti-
hypertensives 
0.95 – 0.99 Original Article Author’s 
judgment 
Weinstein 
and Stason 
0.99 Anti-
hypertensives 
None given Cost-utility 
analysis 
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Quantifying the Utility of Taking Pills for Preventing Adverse Health Outcomes 
 
ABSTRACT 
 
BACKGROUND: Utility measures are used in cost-effectiveness studies to represent the 
effect a given outcome or intervention has on quality of life. Pills are common 
interventions used to try to reduce the risk of an adverse health outcome.  The utility 
value for taking pills is often estimated or assumed to be 1.0, indicating no effect on 
quality of life, but to our knowledge there are few published studies that have 
systematically quantified this utility value. 
OBJECTIVE:  To quantify the utility value of taking pills to prevent an adverse health 
outcome. 
METHODS: We invited healthcare system employees to participate in an online survey 
about taking pills. The main outcome variables were utility values for taking one pill per 
day, two pills per day, and one pill twice daily, all assessed using time trade off. We also 
assessed utility value for taking one pill per day using standard gamble and willingness-
to-pay methods. We compared utility values across several demographic characteristics 
and by numeracy level. 
RESULTS: A total of 708 adults completed the survey. Mean age of respondents was 43 
years. The majority of the respondents were female (83%) and Caucasian (80%).  Almost 
all participants had health insurance (99%), and about 84% had at least an adequate 
numeracy level.  Most (80%) took at least two pills per day. Mean utility values using the 
time trade-off method were: 0.9972 (95% CI 0.9962-0.9981) for one pill daily, 0.9969 
(95% CI 0.9957-0.9979) for two pills daily, and 0.9965 (95% CI 0.9955-0.9975) for 
taking 1 pill twice daily.   The utility values for taking 1 pill daily using the standard 
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gamble and willingness-to-pay methods were 0.9968 (0.9955-0.9980) and 0.9985 (95% 
CI 0.9982-0.9988), respectively. Mean utility values did not vary significantly by age, 
sex, race, education level, income level, or number of pills taken per day. Those with low 
numeracy level tended to have slightly lower utility values. 
CONCLUSIONS: The utility value of taking pills daily in order to prevent an adverse 
health outcome is approximately 0.997, varying slightly depending on the pill regimen 
and utility assessment method used. 
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INTRODUCTION 
 
The desire to take medicine is perhaps the greatest feature which distinguishes  
man from animals. – Sir William Osler 
 
Most adults will end up taking daily pills at some point in their lives.  Many 
adults take multiple pills, often more than once per day.  When people take pills they 
must go through a process that involves, but is not limited to, obtaining the pills, paying 
for them, ingesting the pills, and remembering to take the pills. These processes, part of 
the routine of “taking pills,” can theoretically affect quality of life.  If the pills require a 
prescription or therapeutic monitoring, the process also includes visits to clinicians and 
pharmacists, which may further affect quality of life.  
When people take pills on a daily basis, they do so either to try to prevent an 
undesired health outcome or to treat a specific condition and/or its symptoms.   In both 
cases, there may be some diminution in quality of life attributable to pill-taking.  Side 
effects of pills aside, the effects of pill-taking on quality of life are likely to vary not only 
based on the reason people take pills but also on other factors such as number of pills 
taken per day, number taken at one time, and even the size of the pills.  In health studies, 
effects on quality of life are often measured by assigning a numerical value that 
represents the relative quality of life effect that a certain health state carries versus a 
standard state.  This numerical value is termed a “utility.”  Utilities usually range from 0 
to 1, with 0 representing death and 1 representing perfect health. 
There are many studies that address patient adherence and compliance based on 
quantity and complexity of prescribed medication regimens, as well as studies that 
attempt to quantify patient utilities for outcomes of certain diseases.1-3 However, we are 
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aware of only two studies that included a systematic effort to quantify the utility value of 
taking pills.4-5 In those studies, 57 and 70 patients were interviewed, and using the time 
trade-off utility assessment method, the investigators found a utility value of 0.998 for 
taking daily aspirin in both studies and 0.987 for taking warfarin (including monitoring) 
in one study and 0.988 for taking warfarin in the second study.  There are additional 
studies that cite a utility value or discount value to taking pills,3,6-22 though some of these 
studies seem to have chosen values arbitrarily, based on expert opinion, or based on other 
published articles. 
We conducted a cross-sectional study using an electronic survey to quantify the 
utility of taking pills for the purpose of trying to prevent an adverse health outcome.  
Secondarily, we sought to understand whether the average utility value varies by 
demographics and other characteristics.  Knowing this information will be useful for 
researchers conducting cost-effectiveness analyses or studying the utility of combination 
medications. Additionally, this information may inform interventions designed to 
improve adherence to medication regimens. 
 
METHODS 
Survey Development 
We used a focus group composed of eight people to guide the framing of the 
utility questions for our survey. Specifically, we tested each of the utility value 
measurement methods: rating scale, time trade-off (TTO), willingness-to-pay (WTP), and 
standard gamble (SG).  When asked test questions using the rating scale method (e.g., a 
scale of 0 to 100), it was clear that focus group participants were overestimating the 
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utility of taking pills, often assigning utility values of 0.7 or lower to taking one pill per 
day – a value which would be comparable to non-disabling stroke (0.75).4  The WTP 
method also proved difficult as a measure for pill-taking utility due to most participants 
not being willing to pay anything for an alternative health state.  The standard gamble 
was a difficult concept for focus group participants to grasp, but feedback was used to 
refine an SG question.  The time trade-off method seemed to be the best understood 
method by the focus group participants, providing a range of responses we considered 
most consistent with the likely value for the utility of taking pills. 
Our survey (Appendix) was created using Qualtrics and consisted of initial 
questions about the respondent’s personal pill regimen, as well as questions about how 
specific qualities of pills (e.g., size, shape) affect the difficulty of taking a pill.  Following 
this initial section, we transitioned into the utility measurement section using a series of 
time trade-off method questions.  We also included two additional questions to assess 
utility via a willingness to pay method and a standard gamble method. We included 
questions in order to ascertain numeracy level of each respondent, followed by a final 
section asking for basic demographic information.   
We pilot tested the survey using a convenience sample to gather feedback on ease 
of completion and clarity of questions. Based on feedback, we refined a few items to 
maximize clarity. The study was granted exempt status by the Office of Human Research 
Ethics of the University of North Carolina at Chapel Hill. 
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Participant Selection 
An informational email advertising the study and asking for volunteers was sent 
to all UNC Healthcare employees.  Additionally, an informational newsletter ad was 
placed in the UNC Healthcare employee newsletter and the UNC School of Medicine 
employee newsletter.  An estimated total of 18,500 people were sent the advertisement 
either by email announcement (8,592) or by newsletter ad (10,000).  The only criterion 
for eligibility was age 18 years or older.  
 
Variables 
 The main outcome variables for this study were utility values for taking one pill 
per day, two pills daily, and one pill twice daily.  These values were all obtained using a 
time trade-off utility assessment method. We also obtained a utility value for taking one 
pill per day using both the standard gamble and willingness-to-pay methods.  Participants 
rated difficulty obtaining medications and difficulty paying for medications on a scale 
from 1 to 5.  For analysis, these were then combined into three categories: not difficult, 
neutral, and difficult.  Additionally, numeracy was assessed using a 3-question numeracy 
questionnaire, with overall numeracy level then categorized as either “low” if the 
respondent got 0-1 correct answers or “adequate” if the respondent got 2-3 answers 
correct.23 
 
Data Analysis 
Participant responses to time trade-off, standard gamble and willingness-to-pay 
questions were converted to utility values using Microsoft Excel, after which an analysis 
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was performed using STATA 12 (College Station, TX). The TTO utility value was 
derived by calculating the proportion of time that each respondent was willing to give up 
by the amount of time each respondent had left in his or her life (using an average life 
expectancy of 78 years) and subtracting from 1.  Some survey respondents did not enter 
age in the survey, which prevented us from being able to calculate a time trade-off utility 
value.  Those participants with missing age data (n=95) were excluded from the time 
trade-off utility analysis.   
The utility value for SG was calculated as 1 minus the risk of death the participant 
was willing to accept for the alternate treatment.  The utility value using WTP was 
derived by dividing the amount a participant was willing to pay (to not have to take a pill) 
by their total estimated earnings through an average retirement age of 65 years and 
subtracting from 1. We excluded all participants who did not provide an age (n=95) and 
those who were older than 65 (n=19).  We used the middle value from whichever income 
category the participant selected.  The responses received for WTP varied significantly in 
range, which led to some utility values being considerable outliers.  Therefore, we also 
excluded WTP utility values below 0.95 (n=4).  A total of 118 responses were excluded 
from the WTP analysis. 
We describe basic participant demographics ratings of pill characteristics and 
average utility values using proportions with 95% confidence intervals or means with 
standard deviations.  One-way ANOVA was used to compare utility values by participant 
characteristics.  All utility values were rounded to four decimal places.  A p-value ≤ 0.05 
was used to define statistical significance. 
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RESULTS 
Characteristics of Respondents 
A total of 758 people opened the survey link, with 9 who denied consent.  Of the 
749 who gave consent and began the survey, 708 finished the survey before it was closed 
(Figure 1).  The rate of completion among all who were sent an advertisement about the 
study was 708/18,500 (~3.8%).  Mean age of respondents was 43 years, with more 
participants in the >50 year old category (41%) than either the 18-35 (30%) or the 36-50 
(29%) year old categories (Table 1).  Most participants were female (83%) and Caucasian 
(80%), while almost all participants had health insurance (99%).  Additionally, almost 
half of the participants had annual household incomes greater than $75,000 (48%) while 
about 85% had at least a college degree.  Based on a set of three numeracy questions, 
84% had adequate numeracy and 61% rated their health as very good or excellent. Less 
than 8% of participants reported any degree of difficulty obtaining their pills, while about 
16% of participants reported some degree of difficulty paying for their pills.  
Approximately 65% took at least 3 pills per day, while only 3.7% took no pills per day 
(Table 1).   
 
Pill Characteristics 
Pill size was the most important characteristic affecting difficulty of pill-taking, 
with a mean score of 3.06 on a scale of 1 to 5 where 5 represents the greatest influence on 
difficulty (Table 2).  Shape was the least important characteristic with a mean score of 
2.23. 
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Time Trade-Off Utility Value 
 The overall average utility value using time trade-off revealed a utility of 0.9972 
for taking 1 pill daily, 0.9969 for taking 2 pills daily and 0.9965 for taking 1 pill twice 
daily (Table 3).  Mean utility value was not significantly different by age, sex, race, 
education level, or income level (Table 4). When considering 2 pills daily and one pill 
twice daily, respondents with low numeracy level had slightly lower mean utility values 
compared to those with adequate numeracy level. There also appeared to be slight 
differences based on difficulty obtaining pills.  Although not statistically significant, the 
small number of respondents who indicated currently taking no daily pills did have a 
lower mean value for utility of taking pills than those who took at least 1 pill per day. 
 
Standard Gamble Utility Value 
 Using a standard gamble method, the overall average utility value for taking 1 pill 
daily was 0.9968 (Table 3).  Mean utility value by SG also did not vary by age, sex, race, 
education level, or self-reported health status (Table 5).  As with the TTO, those who 
took no daily pills assigned a lower utility value to taking pills than those who took at 
least 1 pill per day, although the difference was not statistically significant.  Again, those 
with lower numeracy level assigned a lower mean utility value (0.9919 vs. 0.9976, 
P<0.01). 
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Willingness-to Pay Utility Value 
Using a willingness-to-pay utility assessment method, the overall average utility 
for taking one pill daily was 0.9985 (Table 3). With WTP, those in the higher age group 
and those with lower income both had lower mean utility values (Table 5). 
 
DISCUSSION 
The primary goal of this study was to quantify a specific utility value of taking 
pills. We hypothesized that there is some diminution in quality of life attributable to pill-
taking, but that it would be small. Based on our results, we are confident that a reasonable 
utility value for taking a pill daily to try to prevent an adverse health outcome is 0.997. 
The 95% confidence interval for this value is 0.996 to 0.998, and this value appears to 
hold across multiple comparison groups. People who do not take pills on a daily basis 
may rate the act of taking a pill on quality of life as having a greater impact (i.e. lower 
utility) than those who actually do take pills on a daily basis.  Although our sample size 
for this subgroup was small, this finding suggests that moving from a state of taking no 
pills to a state of having to take daily pills may be viewed as having a larger effect 
(though still small overall effect) on quality of life than transitioning from other states 
(e.g., 1 pill to 2 pills).  
Our results are comparable to two prior studies that measured a utility value for 
pill-taking.4-5 Our utility value of 0.997 is similar to the value of 0.998 found in both 
prior studies for taking aspirin. However, our value is higher than the values for taking 
warfarin noted in prior studies: 0.987 and 0.988.  This difference is likely due to the fact 
that those studies included within the utility of taking the pill the additional utility of the 
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INR monitoring and lifestyle limitations such as avoidance of excessive alcohol and 
contact sports. We sought to examine the utility of pill-taking itself, viewing aspects such 
as bothersome side effects, limitations, and any required therapeutic monitoring as 
separate issues.   
We are aware of at least nineteen additional studies that use a utility value of 
taking pills in their analyses.  All of the studies cited values between 0.95 and 1.0, 
depending on the type of pill and whether or not side effects and monitoring were 
considered.3-22  Most of the analytic studies used a value close to 1.0 as their base case 
and then performed a sensitivity analysis to analyze a range.  The lower end of their 
range was generally lower than the values that we obtained in this study. 
A very small change in the utility value assigned to pill-taking can have an 
important effect on cost-effectiveness results.  For example, one study examined whether 
cost-effectiveness of aspirin was sensitive to the assigned utility value of taking the pill.16 
The base case used a utility value of 1.0; the authors then examined the cost per quality-
adjusted life-year (QALY) gained across a variety of utility values for taking aspirin.  In 
that analysis, using any utility value below about 0.9996 caused an increase in the cost 
per QALY above the accepted cost-effective threshold of $50,000/QALY. Such an 
analysis highlights the importance of having an accurate utility value for pill-taking. 
 As expected, as the pill regimen becomes more complex and time-consuming, the 
utility decreases.  From one pill daily to two pills daily to one pill twice daily, the utility 
value incrementally decreased from 0.9972 to 0.9969 to 0.9965, respectively, using the 
TTO method (Table 3).  The SG method and WTP method both revealed similar values 
of 0.9968 and 0.9985, respectively.  These findings, along with our results in Table 2, 
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suggest that two things that can be done to minimize the impact of pill-taking on quality 
of life are keeping pill regimens simple (i.e., once daily) and making pills small in size.  
  
Limitations 
 There are several limitations we acknowledge. First, individuals who are eligible 
to receive informational emails and the newsletter can easily opt out using their email 
filter.  Additionally, many people simply delete informational emails upon receipt into 
their email inbox.  Therefore, we don’t know precisely how many people actually 
received the email and opened it. If the people who did not participate had answered the 
utility questions differently than people who did respond, we would have a nonresponse 
bias.   Our respondents were predominantly women, although we saw no differences in 
utility values by sex. Our respondents were geographically isolated to the Chapel Hill, 
North Carolina area. Although unlikely, it is possible that utility values could vary by 
geographic region.  Our WTP analysis did not account for any participants over the age 
of 65 years and also does not account for any income over age 65, which is not likely. It 
also assumes that a person’s annual income remains stable over a lifetime, which is also 
unlikely.  We therefore have the least confidence in the estimates generated by WTP.  
 
Conclusion 
 The utility value of taking a pill daily to prevent an adverse health outcome is 
approximately 0.997.  Knowing this value is useful for researchers who conduct cost-
utility analyses. It is also relevant to the pharmaceutical industry in considering what 
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people might be willing to pay for combination pills.  Finally, this study reminds 
clinicians that patients appreciate once-daily pill regimens and small pills.  
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Figure 1. Study Participation 
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Table 1. Participant Characteristics 
Characteristic n Number or 
Percent 
 
Mean age 613 43 years 
Age group 
   18-35 years 
   36-50 years 
   >50 years 
613  
29.8% 
29.1% 
41.1% 
% Female 708 83.3% 
Race 
   Caucasian 
   African American 
   Other 
708  
79.8% 
11.3% 
8.9% 
Income 
   < $25,000 
   $25,000 - $75,000 
   >$75,000 
708  
6.1% 
45.6% 
48.3% 
< College degree 708 14.7% 
Numeracy 
   0 correct 
   1 correct 
   2 correct 
   3 correct 
708  
4.4% 
11.9% 
32.6% 
51.3% 
Health* 
   Poor 
   Fair 
   Good 
   Very Good 
   Excellent 
708  
0.6% 
7.2% 
31.5% 
44.8% 
16.0% 
% Insured 708 98.6% 
Difficulty obtaining pills § 
   Somewhat difficult 
   Very difficult 
708  
7.3% 
0.4% 
Difficulty paying for pills §  
   Somewhat difficult 
   Very difficult 
708  
15.0% 
1.1% 
# times pills taken per day  ≥ 2 708 50.6% 
# pills taken per day 
   0 
   1 
   2 
   3+ 
708  
3.7% 
16.0% 
15.5% 
64.8% 
* Self-reported 
§ Rated on 5 point scale  
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Table 2. Participant Rating of Importance of Characteristics of Pills 
Characteristic of Pill Mean Rating* (SD) 
Size 3.06 (1.55) 
Cost 2.74 (1.46) 
Taste 2.66 (1.44) 
Smell 2.33 (1.39) 
Coating 2.31 (1.34) 
Shape 2.23 (1.33) 
* Rated on 5 point scale with 1 indicating that the characteristic does not affect the difficulty of 
taking a pill at all and 5 indicating that the characteristic greatly affects the difficulty of taking 
a pill 
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Table 3. Average Utility Value for Each Outcome 
Assessment Method Utility Value (95% CI) 
Time Trade-Off * 
   1 Pill Daily 
   2 Pills Daily 
   1 Pill Twice a Day 
 
0.9972 (0.9962-0.9981) 
0.9969 (0.9957-0.9979) 
0.9965 (0.9955-0.9975) 
Standard Gamble 
   1 pill daily 
 
0.9968 (0.9955-0.9980) 
Willingness-to-pay € § 
   1 pill daily 
 
0.9985 (0.9982-0.9988) 
* Participants with missing age data removed prior to calculating mean and SD (95 responses 
removed) 
€ Participants with missing age data (n=95) and age ≥ 65 (n=19) removed prior to calculating 
mean and SD (114 responses removed) 
§ Outliers below 0.95 were removed from data prior to calculating mean and SD (4 responses 
removed) 
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Table 4. Mean Utility Values by Participant Characteristics ^ 
 
Characteristic 
 
n 
1 pill daily 2 pills daily 1 pill twice daily 
Mean p value* Mean p value* Mean p value* 
Age (years) 
   18-35 
   36-50 
   >50 
 
211 
206 
196 
 
0.9987 
0.9962 
0.9966 
 
0.07 
 
0.9983 
0.9957 
0.9965 
 
0.0929 
 
0.9975 
0.9957 
0.9962 
 
0.31 
Sex 
   Female 
   Male 
 
519 
  94 
 
0.9974 
0.9959 
 
0.25 
 
0.9970 
0.9963 
 
0.59 
 
0.9966 
0.9959 
 
0.60 
Race 
   African American 
   Caucasian 
   Other 
 
68 
492 
53 
 
0.9964 
0.9974 
0.9959 
 
0.56 
 
0.9954 
0.9972 
0.9959 
 
0.43 
 
0.9949 
0.9969 
0.9949 
 
0.28 
Education Level 
   < College Degree 
   College or Graduate 
degree 
 
84 
529 
 
0.9974 
0.9972 
 
0.88 
 
 
0.9971 
0.9969 
 
 
0.88 
 
 
0.9970 
0.9964 
 
0.68 
 
 
Income 
   < $25,000 
   $25,000 - $75,000 
   >$75,000 
 
33 
277 
303 
 
0.9953 
0.9972 
0.9974 
 
0.64 
 
0.9945 
0.9969 
0.9971 
 
0.50 
 
0.9943 
0.9965 
0.9968 
 
0.54 
Health Rating 
   < Very Good 
   ≥ Very Good 
 
227 
386 
 
0.9967 
0.9975 
 
0.42 
 
 
0.9961 
0.9973 
 
0.26 
 
0.9963 
0.9966 
 
0.74 
 
Numeracy Level ∞ 
   Low 
   Adequate 
 
93 
520 
 
0.9952 
0.9975 
 
0.08 
 
0.9936 
0.9975 
 
< 0.01 
 
0.9941 
0.9969 
 
0.04 
Difficulty Obtaining 
Pills 
   Not difficult 
   Neutral 
   Difficult 
 
 
517 
51 
45 
 
 
0.9976 
0.9924 
0.9978 
 
 
0.01 
 
 
0.9973 
0.9935 
0.9957 
 
 
0.09 
 
 
0.9968 
0.9939 
0.9966 
 
 
0.28 
Difficulty Paying for 
Pills 
   Not difficult 
   Neutral 
   Difficult 
 
 
435 
83 
95 
 
 
0.9978 
0.9935 
0.9979 
 
 
0.01 
 
 
0.9977 
0.9933 
0.9965 
 
 
0.01 
 
 
0.9971 
0.9933 
0.9966 
 
 
0.04 
# times pills taken per 
day 
   < 2    
   ≥ 2 
 
 
303 
310 
 
 
0.9963 
0.9980 
 
 
0.08 
 
 
0.9961 
0.9976 
 
 
0.14 
 
 
0.9955 
0.9975 
 
 
0.04 
# pills taken per day 
   0   
   1 
 
25 
99 
 
0.9936 
0.9969 
 
0.28 
 
0.9944 
0.9966 
 
0.61 
 
0.9941 
0.9956 
 
0.53 
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   2 
   3+ 
96 
393 
0.9987 
0.9971 
0.9980 
0.9968 
0.9976 
0.9966 
^ Utilities derived using time trade-off technique 
* p values based on one-way analysis of variance 
∞ Numeracy level based on number of questions correct on numeracy question (0-1 = Low; 2-3 = 
Adequate) 
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Table 5.  Mean Utility Value of Taking 1 Pill Daily by Participant Characteristics^ 
 
Characteristic 
Standard Gamble Willingness-to-Pay € § 
n Mean p value* n Mean p value* 
Age (years) 
   18-35 
   36-50 
   >50 
 
211 
206 
291 
 
0.9966 
0.9973 
0.9963 
 
0.81 
 
210 
205 
175 
 
0.9995 
0.9987 
0.9971 
 
< 0.01 
 
 
Sex 
   Female 
   Male 
 
590  
118 
 
0.9966 
0.9974 
 
0.62 
 
493 
97 
 
0.9984 
0.9993 
 
0.04 
 
Race 
   African American 
   Caucasian 
   Other 
 
80 
565 
63 
 
0.9934 
0.9973 
0.9957 
 
0.14 
 
 
 
68 
469 
53 
 
0.9981 
0.9986 
0.9981 
 
0.41 
 
 
Education Level 
   < College Degree 
   College or Graduate degree 
 
104 
604 
 
0.9950 
0.9970 
 
0.25 
 
 
80 
512 
 
0.9988 
0.9985 
 
0.47 
 
Income Level 
   <$25,000 
   $25,000-$75,000 
   >$75,000 
 
43 
323 
342 
 
0.9971 
0.9966 
0.9968 
 
0.97 
 
36 
273 
281 
 
0.9967 
0.9982 
0.9990 
 
 < 0.01 
Health Rating 
   < Very Good 
   ≥ Very Good 
 
278 
430 
 
0.9964 
0.9969 
 
0.74 
 
 
233 
357 
 
0.9984 
0.9986 
 
0.71 
Numeracy Level ∞ 
   Low 
   Adequate 
 
115 
593 
 
0.9919 
0.9976 
 
< 0.01 
 
67 
523 
 
0.9986 
0.9985 
 
0.79 
Difficulty Obtaining Pills 
   Not difficult 
   Neutral 
   Difficult 
 
594 
59 
55 
 
0.9971 
0.9962 
0.9925 
 
0.13 
 
500 
48 
42 
 
0.9985 
0.9975 
0.9993 
 
0.09 
Difficulty Paying for Pills 
   Not difficult 
   Neutral 
   Difficult 
 
493 
101 
114 
 
0.9976 
0.9969 
0.9925 
 
0.01 
 
418 
80 
92 
 
0.9986 
0.9977 
0.9986 
 
0.15 
# times pills taken per day 
   < 2 
   ≥ 2 
 
350 
358 
 
0.9961 
0.9973 
 
0.34 
 
295 
295 
 
0.9988 
0.9982 
 
0.10 
# pills taken per day 
   0   
   1 
   2 
   3+ 
 
26 
113 
110 
459 
 
0.9953 
0.9965 
0.9989 
0.9963 
 
0.49 
 
25 
97 
94 
374 
 
0.9994 
0.9985 
0.9991 
0.9983 
 
0.27 
 
^ Utilities derived using standard gamble technique or willingness-to-pay technique, as indicated 
* p values based on one-way analysis of variance 
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€ Participants with missing age data (n=95) and age ≥ 65 (n=19) removed prior to calculating 
mean and SD (114 responses removed) 
§ Outliers below 0.95 were removed from data prior to calculating mean and SD (4 responses 
removed) 
∞ Numeracy level based on number of questions correct on numeracy question (0-1 = Low; 2-3 = 
Adequate) 
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APPENDIX. Survey Items. 
 
What is the effect on quality of life of taking pills? 
 
What is your age? ______ 
 
We’d like to start by asking you a few questions about taking pills, which includes 
capsules, tablets, or gelcaps. 
 
How many pills do you take each day? (Include vitamins and prescription medications 
you take daily but not pills you take only once in a while) 
o 0      (skip next three items) 
o 1 
o 2 
o 3 
o 4 
o 5 
o 6 or more 
How many different times a day do you regularly take pills? 
o Once per day 
o 2 times per day 
o 3 times per day 
o More than 3 times per day 
How difficult is it for you to pay for your pills? 
o Very difficult 
o Somewhat difficult 
o Neutral 
o Not very difficult 
o Not difficult at all 
How difficult is it for you to obtain for your pills? 
o Very difficult 
o Somewhat difficult 
o Neutral 
o Not very difficult 
o Not difficult at all 
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Rate the extent to which each of the following characteristics of a pill affect the difficulty 
of taking a pill, where 1 indicates no effect at all and 5 indicates a large effect.  
 1 
Does not 
affect at all 
2 3 4 5 
Greatly 
affects 
difficulty 
Size ∘ ∘ ∘ ∘ ∘ 
Taste ∘ ∘ ∘ ∘ ∘ 
Smell ∘ ∘ ∘ ∘ ∘ 
Shape ∘ ∘ ∘ ∘ ∘ 
Coating ∘ ∘ ∘ ∘ ∘ 
Cost ∘ ∘ ∘ ∘ ∘ 
 
Please read the following carefully: 
The next set of questions pertains to taking pills to PREVENT a heart attack and stroke.  
Assume that by taking these pills you will live your life free of heart attack and stroke. 
Assume that the pills do not cause any side effects and are free of charge. However, you 
do have to obtain a prescription from your doctor in order to get them, fill the 
prescription at the pharmacy, remember to take the pill every day, and physically 
swallow the pill.      
Now assume that you have a choice.  Instead of taking the pill every day, you could give 
up time at the end of your life and also be guaranteed to live a life free of heart 
attacks and stroke.   
Approximately how much of your remaining life would you give up in order to NOT 
have to take this 1 pill every day for the rest of your life? 
o None 
o 2 weeks 
o 1 month 
o 3 months 
o 6 months 
o 9 months 
o 12 months 
o 18 months 
o 24 months 
 
 
 
 
	   43	  
How about if you were taking two such pills, at the same time of day (for example: 2 pills 
in the morning)? 
o None 
o 2 weeks 
o 1 month 
o 3 months 
o 6 months 
o 9 months 
o 12 months 
o 18 months 
o 24 months 
How about if you were taking two such pills, at two DIFFERENT times of day (for 
example: 1 pill in the morning, 1 pill at night)? 
o None 
o 2 weeks 
o 1 month 
o 3 months 
o 6 months 
o 9 months 
o 12 months 
o 18 months 
o 24 months 
 
 
Imagine that you have been diagnosed with a health condition that, if not treated, will 
limit the quality and length of your life.  The physician who diagnoses you tells you that 
there are two known treatments, both of which will cure you completely. 
Treatment 1 is a one-time treatment that cures you but happens to also have the potential 
to cause immediate death. 
Treatment 2 is a pill you have to take once a day every day for the rest of your life.  
There is 0% risk of death from this pill. 
Approximately what chance of immediate death are you willing to risk to take Treatment 
1 one time instead of taking Treatment 2 every day for the rest of your life? 
o 100,000 in 1,000,000 
o 10,000 in 1,000,000 
o 1,000 in 1,000,000 
o 100 in 1,000,000 
o 10 in 1,000,000 
o 1 in 1,000,000 
o 0.1 in 1,000,000 
o 0 in 1,000,000 
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Assume you will work until you are 65 years of age.  You can get treatment 1 for a one-
time payment.  Approximately how much would you be willing to pay to receive 
Treatment 1 one time instead of taking Treatment 2 every day for the rest of your life? 
$__________ 
 
Next, we would like to ask you a few questions about chance and working with 
numbers.   For each question, please give us your best estimate, even if you think 
your estimate is only a guess. 
A person taking Drug A has a 1% chance of having an allergic reaction.  If 1,000 people 
take Drug A, how many people would you expect to have an allergic reaction? 
  # of people =  ________ 
 
The next question asks how many times something would happen in 1,000 tries. 
Example:  Imagine picking a jelly bean from a jar filled with an equal number of 4 
different colored jelly beans (red, black, blue and green).  Out of 1,000 tries, how many 
times would you expect to pick a red jelly bean?        
Answer:     250 times out of 1,000 
Now you try: Imagine that we flip a coin 1,000 times.  What is your best guess about how 
many times the coin would come up heads in 1,000 flips? 
   # heads in 1,000 flips = _____________ 
 
Just a few final questions… 
What is your gender? 
o Male 
o Female 
What best describes your race/ethnicity? 
o African American 
o Asian 
o Caucasian 
o Native American 
o Pacific Islander 
o Other/None of the above 
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What is your highest level of education completed? 
o Less than high school 
o High school or GED 
o Some college 
o College degree 
o Graduate or professional degree 
How would you rate your overall health? 
o Poor 
o Fair 
o Good 
o Very Good 
o Excellent 
Do you have health insurance? 
o No 
o Yes 
What is your total household income? 
o <$10,000 
o $10,000-$24,999 
o $25,000-$49,999 
o $50,000-$74,999 
o $75,000-$99,999 
o $100,000-$150,000 
o >$150,000 
 
 
